DAX24.539 +0,2%Est505.850 +1,0%MSCI World4.343 -0,1%Top 10 Crypto12,27 +3,7%Nas23.236 ±-0,0%Bitcoin76.727 +0,1%Euro1,1730 ±0,0%Öl60,75 -0,3%Gold4.330 +0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA SAP 716460 Bayer BAY001 Tesla A1CX3T Deutsche Telekom 555750 Lufthansa 823212 Novo Nordisk A3EU6F Siemens Energy ENER6Y Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 BYD A0M4W9 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht freundlich ins Wochenende -- Wall Street letztlich uneins -- Entscheidung über Luftkampfsystem FCAS erneut vertagt -- Goldpreis, Commerzbank, DroneShield, Nike, Stahlaktien im Fokus
Top News
Grayscale-Prognose: Bitcoin könnte 2026 neue Rekordhöhen erreichen Grayscale-Prognose: Bitcoin könnte 2026 neue Rekordhöhen erreichen
Jetzt Neujahrsbonus sichern: 3 Geschenke für Neukunden bei unserem Broker finanzen.net ZERO Jetzt Neujahrsbonus sichern: 3 Geschenke für Neukunden bei unserem Broker finanzen.net ZERO
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Merck Aktie

Kaufen
Verkaufen
Merck Aktien-Sparplan
91,20 EUR +0,80 EUR +0,89 %
BMN
106,40 USD -0,09 USD -0,08 %
nachbörslich
BTT
Merck jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.222,73 Mrd. EUR

KGV14,77Div. Rendite3,14%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0YD8Q

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS58933Y1055

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolMRK

Merck Aktien News

DatumMeistgelesen
PR NewswireSaskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)
PR NewswireQuebec Expands Public Funding for CAPVAXIVE®
Wer­bungMerck-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR Newswireeschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
PR NewswireHealth Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adju...
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹
PR NewswireMerck Commits to Veeva Vault CRM
PR NewswireMerck entscheidet sich für Veeva Vault CRM
PR NewswireMerck Commits to Veeva Vault CRM
PR NewswireHealth Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireMRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireClass Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireMRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireMRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireLevi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
PR NewswireHealth Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as ...
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireMerck & Co., Inc. Class Action: The Gross Law Firm Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
PR NewswireMerck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
PR NewswireMerck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
PR NewswireMRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
PR NewswireMRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireMRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireClass Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky
PR NewswireMRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireHealth Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination w...
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...

Merck News

Merck News: auf dieser Seite finden Sie alle Merck News und Nachrichten zur Merck Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merck News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merck News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.